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Downstream regulatory element antagonist modulator (DREAM) is a Ca2+-binding pro-
tein that binds DNA and represses transcription in a Ca2+-dependent manner. Previous
work has shown a role for DREAM in cerebellar function regulating the expression of the
sodium/calcium exchanger 3 (NCX3) in cerebellar granular neurons to control Ca2+ home-
ostasis and survival of these neurons. To achieve a global view of the genes regulated
by DREAM in the cerebellum, we performed a genome-wide analysis in transgenic cere-
bellum expressing a Ca2+-insensitive/CREB-independent dominant active mutant DREAM
(daDREAM). Here we show that DREAM regulates the expression of the midline 1 (Mid1)
gene early after birth. As a consequence, daDREAM mice exhibit a signiﬁcant shortening
of the rostro-caudal axis of the cerebellum and a delay in neuromotor development early
after birth. Our results indicate a role for DREAM in cerebellar function.
Keywords: midline 1, cerebellar lobes, nuclear calcium, transcriptomic analysis
INTRODUCTION
Downstreamregulatory element antagonistmodulator (DREAM),
also named calsenilin or KChIP-3, is a Ca2+-binding protein of
the neuronal calcium sensors family able to repress transcription
of speciﬁc genes in a Ca2+-dependent manner (Carrion et al.,
1999), to interact with presenilins and to modify APP processing
(Buxbaum et al., 1998; Lilliehook et al., 2003) and to regulate the
membrane expression and gating of Kv4 potassium channels (An
et al., 2000; Ruiz-Gomez et al., 2007) and of voltage-dependent
calcium channels (Thomsen et al., 2009; Anderson et al., 2010). In
addition, DREAM modulates downstream signaling of different
membrane receptors including NMDA (Wu et al., 2010; Zhang
et al., 2010) and THSR (Rivas et al., 2009).
Transcriptional activity of DREAM is triggered by its
sumoylation-dependent nuclear translocation (Palczewska et al.,
2011), regulated by redox state (Rivas et al., 2011), and accom-
plished by its Ca2+-dependent speciﬁc binding to DNA and to
other nucleoproteins, including CREM and CREB (Ledo et al.,
2000, 2002; Rivas et al., 2004; Scsucova et al., 2005; Zaidi
et al., 2006). In addition, high afﬁnity binding of DREAM to
DRE sequences in the DNA requires Ca2+-dependent DREAM
oligomerization (Carrion et al., 1998; Osawa et al., 2001, 2005).
Downstream regulatory element antagonist modulator is
widely expressed in the central nervous system as well as in the
thyroid gland, testis, and the immune system (Carrion et al.,
1999). Tissue-speciﬁc target genes for DREAM regulation have
been identiﬁed ﬁrst in vitro (Carrion et al., 1999; Link et al.,
2004) and more recently in vivo, using DREAM null mice (Cheng
et al., 2002) and especially transgenic mice expressing a dom-
inant active DREAM mutant (daDREAM; Gomez-Villafuertes
et al., 2005; Savignac et al., 2005, 2010; Rivera-Arconada et al.,
2010). Speciﬁcally, a signiﬁcant increase in prodynorphin mRNA
was found in spinal cord from DREAM null mice (Cheng et al.,
2002) and a decrease in NCX3 and BDNF mRNA and protein
levels were reported in hippocampus and cerebellum (Gomez-
Villafuertes et al., 2005) and in spinal cord (Rivera-Arconada
et al., 2010) respectively, from daDREAM mice. The regulatory
effect of daDREAM on the expression of transcriptional targets
was shown to be speciﬁc, since for instance no change in the
expression of other members of the sodium/calcium exchanger
family could be observed in hippocampus and cerebellum of
daDREAM transgenic mice (Gomez-Villafuertes et al., 2005). As
expected, transcriptional regulation by DREAM of various cellu-
lar targets has diverse and tissue-speciﬁc functional consequences.
In the CNS, this includes changes in sensory noxious percep-
tion (Cheng et al., 2002; Rivera-Arconada et al., 2010), β-amyloid
accumulation (Lilliehook et al., 2003), and learning and memory
formation (Alexander et al., 2009), as well as modiﬁed T-cell pro-
liferation and Ig production (Savignac et al., 2005, 2010) in the
immune system.
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Taking the cerebellum as an example, previous work using
primary cultures of cerebellar granular neurons has shown the
role of DREAM in the regulation of NCX3 expression, which in
turn is fundamental for the maintenance of Ca2+ homeostasis and
viability of the cerebellar granular neurons in the culture (Gomez-
Villafuertes et al., 2005). In the present study, to further investigate
the functional involvement of DREAM-mediated transcription in
cerebellar function, we have performed a transcriptomic analysis
of the cerebellum from daDREAM transgenic mice.We found that
expression of themidline 1 gene (Mid 1) is repressed in daDREAM
mice. Related to this, daDREAM mice exhibit a signiﬁcant short-
ening of the rostro-caudal axis of the cerebellum and a severe delay
in neuromotor development early after birth.
RESULTS
GENOME-WIDE ANALYSIS IN daDREAM CEREBELLUM
To search for DREAM transcriptional targets that could disclose
a role for DREAM in cerebellar function, we performed genome-
wide analysis in a line of transgenic mice previously reported to
express daDREAM in the cerebellum (Gomez-Villafuertes et al.,
2005).Comparisonof basal gene expression inwild type and trans-
genic adult cerebellum, using cDNA microarrays, identiﬁed only
11 genes whose expression was signiﬁcantly altered in daDREAM
transgenic cerebellum (Gene ExpressionOmnibus accession num-
ber GSE34765; Figure 1). Up- and down-regulated genes are
presented in Table 1 and the bioinformatics analysis is shown in
Tables A1 and A2 in Appendix.
Among the genes with modiﬁed expression (Table 1), we
focused our attention on the signiﬁcant down regulation of the
Mid 1 gene, an ubiquitin ligase speciﬁc for the protein phos-
phatase 2A (PP2A; Trockenbacher et al., 2001). Loss of function
mutations in the Mid1 protein cause the X-linked Opitz BBB/G
syndrome, a congenital anomaly disorder characterized by devel-
opmental defects of midline structures (Opitz, 1987;Quaderi et al.,
1997). Importantly, Mid1 deﬁcient mice mimic the hypoplasia of
the anterior portion of the medial cerebellum (Lancioni et al.,
FIGURE 1 | Genome-wide analysis in daDREAM and wild type
cerebellum. Statistical values and scatter plot of all probes contained in the
genome-wide analysis. Spots with |Fold Change| >1.6 and FDR <0.1 are
highlighted in green (repressed genes) and red (induced genes).
2010), a clinical feature present in Opitz patients, suggesting that
DREAM, through the regulation of Mid1, might participate in
cerebellar development. Real-time qPCR analysis conﬁrmed the
reduced level of Mid1 mRNA in the cerebellum of adult trans-
genic mice as well as in the hippocampus (Figure 2A), areas with
signiﬁcant expression of daDREAM (Figure 2B). As reported for
other DREAM target genes like prodynorphin in the hippocam-
pus (Cheng et al., 2002) or CANT1 in the cerebellum (Cali et al.,
2012), probably due to functional compensation by other mem-
bers of the KChIP family, no change in the expression of Mid1 was
observed in cerebellum or hippocampus from DREAM knockout
mice (Figure 2C). Western blot analysis of cerebellum and hip-
pocampus from daDREAM mice conﬁrmed the reduced levels of
Mid1 protein with respect to wild type mice (Figure 2D). Taken
together, these results implicate endogenous DREAM/KChIPs in
the regulation of Mid1 gene expression in the brain.
DREAM REGULATES EARLY POSTNATAL Mid1 EXPRESSION
Mid1 is widely expressed at early human embryonic stages, how-
ever during organogenesis the expression pattern becomes more
restricted to the tissues affected in the Opitz syndrome (Pinson
et al., 2004). The development of the cerebellum in mice is mostly
postnatal and is complete after the second week of life (reviewed
in Millen and Gleeson, 2008). To investigate a role for DREAM in
the regulation of Mid1 and cerebellar development, we next ana-
lyzed the expression of the daDREAM transgene during cerebellar
development and the consequences onMid1 expression. Real-time
qPCR analysis showed that the expression of daDREAM in the
cerebellum was very high early after birth (P2) and got down at
P7–P21 (Figure 3A) to values slightly higher than adult levels (see
Figure 2B). Expression of Mid1 in wild type cerebellum was high
early after birth (P2–P7) and reached adult levels at P21 (notice
the different scale in Figure 2A). Expression of daDREAM was
associated with a signiﬁcant reduction of Mid1 mRNA levels in
transgenic cerebellum (Figure 3A). Early postnatal expression of
the transgenewas not exclusive to the cerebellumandwas observed
as well in other brain areas, like the hippocampus (Figure 3B).
Expression of daDREAM in the hippocampus was also associated
with a signiﬁcant reduction of Mid1 mRNA levels (Figure 3B).
CEREBELLAR MORPHOLOGICAL CHANGES IN daDREAM MICE
Absence of Mid1 protein in Mid1 null mice results in abnormal
formationof the anterobasal cardinal lobe,which is evident already
at P0–P2 (Lancioni et al., 2010). In adult Mid1 null mice, although
abnormal in shape, even the anterior vermal lobes maintain the
correct layer organization and thickness (Lancioni et al., 2010).
According to the signiﬁcant reduction in Mid1 expression, adult
daDREAM mice showed a signiﬁcant shortening in the antero-
posterior axis but also in the left–right axis (Figures 4A,B). Sagittal
sections from P15 wild type and daDREAM mice conﬁrmed a cor-
rect layer organization of transgenic cerebellum and showed the
shortening of the rostro-caudal axis (Figure 4C).
IMPAIRED MOTOR DEVELOPMENT IN daDREAM MICE
Absence of Mid1 protein in Mid1 null mice has been associated
with impaired motor coordination in the adulthood. To assess
possible changes during early postnatal development that could be
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Table 1 | List of induced and repressed genes in daDREAM vs. wild type cerebellum.
Fold change P -value×10−5 FDR Probe ID Transcript ID Gene symbol Gene description
1.70 0.922 0.023 1440557_at Mm.186257.1 Ipw Imprinted gene in the Prader–Willi syndrome region
1.75 1.792 0.038 1436733_at Mm.40013.1 E130309F12Rik RIKEN cDNA E130309F12 gene
1.86 0.914 0.026 1460049_s_at Mm.213028.1 1500015O10Rik RIKEN cDNA 1500015O10 gene
1.95 0.319 0.0160 1417654_at Mm.3815.1 Sdc4 Syndecan 4
2.10 0 0 1449340_at Mm.43375.1 Sostdc1 Sclerostin domain containing 1
−4.68 0.035 0.000 1436240_at Mm.216255.1 B230214O09Rik RIKEN cDNA B230214O09 gene
−4.17 0.177 0.016 1431214_at Mm.157900.1 LOC433762 Hypothetical gene LOC433762
−2.95 0.133 0.027 1440139_at Mm.174301.1 gb:BB729836 Moderately similar to S12207 hypothetical protein
−2.83 0.231 0.030 1438239_at Mm.24820.1 Mid1 Midline 1
−2.60 0.408 0.037 1425545_x_at Mm.33263.2 H2-D1 Histocompatibility 2, D region locus 1
−2.38 0.639 0.048 1419327_at Mm.22635.1 Pdxdc1 Pyridoxal-dependent decarboxylase domain containing 1
Genes with FDR <0.05 were included in the list of induced or repressed candidates.
FIGURE 2 | Real-time qPCR and western blot analysis of Mid1
expression in adult brain. Levels of Mid1 (A,C) and daDREAM (B) mRNA
in the cerebellum (Cb) and the hippocampus (Hipp) from wild type (wt),
transgenic (tg), and DREAM−/− (KO) mice are shown. Values are normalized
with respect to HPRT mRNA content. Results are the mean±SEM of
14–18 mice in three independent experiments. *P <0.05 (two-tailed,
unpaired t -test) relative to wild type mice. (D) Immunoblot analysis of adult
brain cerebellum and hippocampal lysates (50μg) shows that the 70- to
75-kDa expected band for the Mid 1 protein is reduced in transgenic
compared to wild type mice. β-Actin was used as protein loading control.
The experiment, in duplicates, was repeated twice.
related to Mid1 down regulation in daDREAM mice, we employed
a test battery consisting of somatometric, neurologic, and senso-
rial and motor tests. No differences in somatometric growth, or
in the appearance of developmental landmarks, i.e., eye opening,
FIGURE 3 | Real-time qPCR analysis of Mid1 expression during
postnatal development. Levels of daDREAM and Mid1 mRNA at the
indicated postnatal day from wild type (wt) and transgenic (tg) mice in
cerebellum (A) and hippocampus (B) are shown. Values are normalized
with respect to HPRT mRNA content. Results are the mean±SEM of 8–12
mice in two independent experiments. *P <0.05, **P <0.01, ***P<0.001
(two-tailed, unpaired t -test) relative to wild type mice.
fur appearance, or incisor eruption, were detected in daDREAM
mice. However, signiﬁcant changes were observed in neuromo-
tor development as assessed by the pivoting and the walking tests
on postnatal days 7, 10, and 14. In the pivoting locomotion task,
wild type, and daDREAM mice showed similar activity at P7.
However, the normal age-dependent increase in activity, which is
reﬂecting the adequate maturation of motor systems in wild type,
was signiﬁcantly reduced in daDREAM mice at P10 (Figure 5A).
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FIGURE 4 | Anatomical analysis of adult and postnatal cerebellum.
(A) Image of whole adult mouse brain showing the left–right and
rostro-caudal axis used for the measurement. (B) Measurement of
left–right and rostro-caudal axis of the cerebellum in wild type and (wt)
transgenic (tg) adult mice (n =6). *P <0.05, **P<0.01 (two-tailed,
unpaired t -test) relative to wild type mice. (C) For comparison, sagittal
sections through the cerebellar vermis of postnatal P15 wild type (wt) and
transgenic (tg) mice after staining with hematoxylin/eosin are shown.
Assessment of walking activity conﬁrmed the hypoactive pheno-
type in daDREAM mice and, even at P7 the latency to walk in
transgenic mice was signiﬁcantly longer than in wild type mice
(Figure 5B). At P10, the reduction in walking latency observed
in wild type (33.6% of reduction, P7 vs. P10) was signiﬁcantly
less pronounced in daDREAM mice (10.8% reduction, P7 vs. P10;
Figure 5B). This result, along with the affected pivoting activity
in daDREAM mice, could suggest a supraspinal deﬁciency, indi-
cating that the postnatal development of brain structures directly
implicated in the motor function might be affected in daDREAM
mice. This defect is speciﬁc of motor function, since daDREAM
mice showed normal latency to reach their nest in the homing test
compared to wild types (Figure 5C). This normal latency might
suggest a normal development of other functional domains such
as sensory perception.
DISCUSSION
Genome-wide analysis of different tissues or brain areas from
daDREAM transgenic mice has rendered discrete lists of poten-
tial DREAM regulated genes with some overlapping as well as
tissue-speciﬁc targets (Savignac et al., 2010; Jose R. Naranjo,
unpublished observations). In all cases, including the present data,
these lists include both repressed and induced genes suggesting
that besides the direct repressor action of DREAM, interactions
between DREAM and other transcriptional regulators (Ledo et al.,
FIGURE 5 | Neuromotor development in postnatal mice. Behavioral
analysis (A) pivoting test, (B) walking test, and (C) homing test were
performed at the indicated postnatal days in wild type and (wt) transgenic
(tg) mice (n =16–18). *P <0.05, ***P<0.001 (two-tailed, unpaired t -test)
relative to wild type mice.
2002; Rivas et al., 2004, 2011; Scsucova et al., 2005; Zaidi et al.,
2006) or indirect/secondary transcriptional effects might con-
tribute to gene induction in daDREAM transgenic tissues. In the
case of the daDREAM cerebellum, the list of genes with modi-
ﬁed expression is especially short. This is not related to technical
problems with the hybridization of the array since the bioinfor-
matics analysis of the hybridization signals (see Figure 1) shows
a perfectly normal distribution. Instead, the low number of hits
might reﬂect the limitation of the technique, showing for instance
a minor and not signiﬁcant down regulation (−1.15-fold; P-value
0.06) of the NCX3 gene (also named Slc8a3: solute carrier family
8) previously validated as a direct DREAM target and shown to be
repressed by more than 50% in daDREAM cerebellum (Gomez-
Villafuertes et al., 2005). Alternatively, the low number of targets
may simply reﬂect the limited but speciﬁc functionality of DREAM
in the cerebellum, a brain region where DREAM expression shows
the lowest level among the different areas in the CNS (Carrion
et al., 1999; Rhodes et al., 2004).
Among induced genes, syndecan 4 is a transmembrane pro-
teoglycan for which there are no reports relating a function in
brain or cerebellum. Sclerostin domain containing 1 (Sostdc1) is
a secreted inhibitor of the Wnt and Bmp pathways, that antago-
nizes BMP signaling in the mesenchymal induction of teeth and
orofacial morphogenesis, regulating also the spatial patterning of
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teeth and hair. Deletion of Sostdc1 leads to the full development
of single extra incisors adjacent to the main incisors (Munne et al.,
2009).On the other hand, induced expression of sclerostin domain
containing 1 (Sostdc1) has been reported in the brain of mice deﬁ-
cient in phenylalanine hydroxylase (PAH), an animalmodel for the
autosomal recessive disorder phenylketonuria (Park et al., 2009),
though the functional meaning of this increased expression is not
known. In daDREAM mice, however, induced levels of Sostdc1 do
not have an effect on dentation and hair appearance since both are
normal.
Among repressed genes, the Mid1 protein is biochemically
well characterized and a role in brain development has been
reported. Thus, early studies of Mid1 function recognized its
ubiquitin ligase activity and have identiﬁed its speciﬁc role in
the degradation of protein phosphatase 2A by the proteosome
(Trockenbacher et al., 2001). Importantly, PP2A is the major
serine–threonine–tau phosphatase in the brain and dephospho-
rylates also other microtubule-associated proteins like 4EBP1 and
p70S6K, two targets of the mTOR kinase (Nojima et al., 2003).
Loss of function mutations of the Mid1 protein are associated
with developmental midline malformations present in Opitz syn-
drome patients (Opitz, 1987; Quaderi et al., 1997). Furthermore,
cells derived fromOpitz syndromepatients showdecreased forma-
tion of mTORC1, the complex between mTOR and its interacting
proteins Raptor and mLST8, as well as S6K1 phosphorylation,
cell size, and cap-dependent translation. Expression of wild type
Mid1 or activatedmTORprotein rescue the phenotype, suggesting
that mTORC1 plays a key role in Opitz syndrome pathogene-
sis (Liu et al., 2011). In addition, a recent study has identiﬁed
the binding of the cytoskeletal-associated Mid1/α4/PP2A complex
to polyribosomes and mRNAs via a purine-rich sequence motif
called MIDAS (MID1 association sequence) increasing the stabil-
ity and translational efﬁciency of these mRNAs (Aranda-Orgilles
et al., 2011). Notably, the MIDAS motif is frequent in mRNAs
related to development and energy metabolism and mutated Mid1
does not interact with MIDAS-containing mRNAs suggesting that
defects associated with the Opitz syndrome could be produced
by altered protein translation of some of these mRNAs (Aranda-
Orgilles et al., 2011). About the mechanism by which Mid1 could
affect brain development it has been hypothesized that by control-
ling PP2A activity, Mid1 is regulating the activity of Gli3 (Krauss
et al., 2008) a Wnt target gene related to the development of the
hippocampus (Hasenpusch-Theil et al., 2012), which has been
implicated in three human pathological conditions sharing com-
mon features with Opitz syndrome (Biesecker, 2006). Lack of the
murine Mid1 gene results in motor coordination defects as well
as motor, non-associative, and procedural learning impairments
that may correlate with the developmental delays of Opitz syn-
drome patients (Lancioni et al., 2010). The behavioral analysis
in this study was done in adult mice with no speciﬁc focus on
postnatal development. Our data report an early down regula-
tion of Mid1 expression in daDREAM mice and suggest a delayed
neuromotor development in these mice. Down regulation of Mid1
mRNA levels is not restricted to the cerebellumand is also observed
in the hippocampus, a brain area with strong expression of the
daDREAM mutant. Whether hippocampal morphology is altered
in daDREAM mice and to what extent the reduction in other
genes like NCX3 contribute to the morphological and neuromotor
phenotypes remain to be investigated.
As expected for a proteinwith developmental functions, expres-
sion of Mid1 in adult brain is reduced compared to postnatal
levels. Interestingly, however, expression in the adult hippocam-
pus is higher than in the adult cerebellum. This may suggest a
speciﬁc function for Mid1 in adult hippocampus and the existence
of strong trans-activating mechanisms to compensate a presum-
able stronger repression due to higher levels of DREAM protein in
hippocampus compared to cerebellum.
Analysis of the post-transcriptional regulation of the Mid1
mRNA has shown that alternative use of different transcrip-
tion start sites, alternative splicing, and the existence of different
polyadenylation signal results in a wide variety of Mid1 isoforms
(Landry and Mager, 2002; Winter et al., 2004). Less is known,
however, about the transcriptionalmechanisms that regulateMid1
expression. Like in the case of the BDNF gene, another example
of a gene with multiple transcription start sites, speciﬁc regula-
tory regions have been assigned to each transcription start site.
Interestingly, in silico analysis of these different promoters, both in
the human and the mouse genes, has identiﬁed putative DRE sites
(Table 2), mostly located in the complementary strand, a circum-
stance previously reported for DRE sites in the ICER (Link et al.,
2004) and the interferon γ (Savignac et al., 2005) genes. Neverthe-
less, in vitro analysis of the ability of these sites to bind recombinant
DREAM and especially chromatin immunoprecipitation studies
should conﬁrm the in silico predictions.
In conclusion, the results from the genome-wide analysis
of the cerebellum from daDREAM mice indicate that endoge-
nous DREAM, in addition to regulate NCX3, might also con-
tribute to cerebellar function through the regulation of Mid1 gene
expression.
MATERIALS AND METHODS
TRANSGENIC MICE
A cDNA encoding human DREAM with two amino acid sub-
stitutions at EF-hands 2, 3, and 4 and at the N-terminal LCD
Table 2 | Downstream response elements, DREs, present in the 5′
untranslated region of different Mid1 isoforms.
Species Isoform Position in mRNA Sequencea,b Orientation
Mouse Var 1c 155–164 tgatgacccc ←
Var 2 68–78 cttgacattgt ←
Var 2 261–270 gggtcatgga ←
Human Var 1 317–328 gggtcatggga →
Var 2d 161–173 ctgatgacaca ←
Var 4 158–168 taatgactcca ←
Var 4 259–268 aatgacgtaa ←
aThe core sequence is underlined.
bFor comparison the mouse interferon γ DRE site in the complementary strand
(←) is atcggctgacctagag and the human dynorphin forward element (→) is agc-
cggagtcaaggag.
cThe same element is present in mouse variant 2 at position 316–327.
dThe same element is present in variants 1, 3, 6, 7, 8, and 9.
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(daDREAM) was cloned downstream of the human CaMK-IIα
promoter (Mayford et al., 1995) in a bicistronic expression vec-
tor containing an IRES and the LacZ reporter gene. DREAM
transgenic mice were prepared by pronuclear microinjection of
this cassette in the C57BL/6xCBA hybrid background. Trans-
genic progeny were identiﬁed by Southern blotting and qual-
itative PCR of tail DNA using speciﬁc primers; forward 5′-
TTGCAGTGCACGGCAGATACACTTGCTGA-3′ and reverse 5′-
CCACTGGTGTGGG CCATAATTCAATTCGC-3′. An ampliﬁed
fragment of 326 bp indicated the presence of the transgene.
Founder males were backcrossed to C57BL/6 females to gen-
erate lines that were maintained as heterozygous and age- and
sex-matched littermates were used as controls. Of the different
transgenic lines generated, in this study we used transgenic line 33
that shows expression of the transgene in different brain areas,
including the cerebellum (Gomez-Villafuertes et al., 2005; Wu
et al., 2010).
MICROARRAY
RNA from whole cerebellum from wild type and transgenic mice
was prepared using TRIzol (Invitrogen) and the RNAeasy Mini Kit
(Qiagen). RNA was quantiﬁed and the quality was assessed with
a 2100 Bioanalyzer (Agilent technologies). cDNA was synthesized
from 4μg of total RNA using one-cycle target labeling and con-
trol reagents (Affymetrix) to produce biotin labeled cRNA. The
cRNA preparation (15μg) was fragmented at 94˚C for 35min
into 35–200 bases in length. Labeled cRNAs were hybridized to
Affymetrix chips (GeneChip Mouse Genome 430 2.0 Array). Each
sample was added to a hybridization solution containing 100mM
2-(N -morpholino) ethanesulfonic acid, 1M Na+, and 20mM of
EDTA in the presence of 0.01% of Tween-20 to a ﬁnal cRNA con-
centration of 0.05 μg/ml. Hybridization was performed for 16 h at
45˚C. Each microarray was washed and stained with streptavidin–
phycoerythrin in a Fluidics station 450 (Affymetrix) and scanned
at 1.56μm resolution in a GeneChip® Scanner 3000 7G System
(Affymetrix).
MICROARRAY DATA ANALYSIS
Three biological replicates were independently hybridized for each
cell type. GeneChip intensities were background-corrected, nor-
malized and summarized by the RMA method (Irizarry et al.,
2003) using the “Affy” package (Gautier et al., 2004) from Biocon-
ductor. Rank Products method (Breitling et al., 2004) was applied
to identify differentially expressed genes as implemented in the
“RankProd”package (Hong et al., 2006) fromBioconductor.Genes
with FDR <0.05 were included in the list of induced or repressed
candidates. FIESTA viewer was used to facilitate the application of
these numerical ﬁlters and the selection of candidate genes (Oliv-
eros, 2007). For the functional annotation of the resultsGeneCodis
3.0 was used (Nogales-Cadenas et al., 2009) applying a hyperge-
ometric distribution and a FDR threshold of 0.05 for detecting
over-represented Gene Ontology terms in candidate genes.
REAL-TIME QUANTITATIVE PCR
RNA was isolated from whole tissues using TRIzol (Invitrogen),
treated with DNAse (Ambion), and reverse transcribed using
hexamer primer and Moloney murine leukemia virus reverse
transcriptase. To conﬁrm the absence of genomic DNA, each
sample was processed in parallel without reverse transcriptase.
Real-time quantitative PCR (qPCR) for endogenous DREAM, and
daDREAM was performed as described (Savignac et al., 2005).
Validation of microarray up- or down-regulated genes was with
speciﬁc primers and TaqMan MGB probes (Applied Biosystems).
The results were normalized as indicated by parallel ampliﬁcation
of HPRT.
WESTERN BLOT ANALYSIS
Fifty micrograms of total protein from cerebellum or hippocam-
pus were resolved in SDS-PAGE and transferred to PVDF mem-
branes (Millipore). Antibodies against Mid1 (Ab 70770, Abcam)
and β-actin (Sigma) were used.
ANATOMICAL ANALYSIS
For observation of adult cerebellum, 2-months-old wild type and
transgenic mice were anesthetized and whole brains were carefully
removed from the skull. Coronal and sagittal sections were taken
and measurements of left–right and rostro-caudal axis were per-
formed. For histological analysis, brains from 15-days-old pups
(P15) were harvested and ﬁxed in 4% paraformaldehyde for 48 h
at 4˚C. Brains were processed for parafﬁn embedding and micro-
tome sectioning. Brain sagittal sections of 10 μmwere stainedwith
hematoxylin/eosin using standard procedures.
BEHAVIORAL ANALYSIS
Experiments were performed in newborn mice homozygous for
the transgene and wild type littermates. Mice were initially housed
in a temperature (21± 1˚C) and humidity (65± 10%) controlled
room with a 12/12-h light/dark cycle (lights on from 0800 to
2000 hours) with ad libitum food and water. Breeding pairs were
formed and females visibly close to parturition were isolated. To
avoid the effects of parity on behavioral ontogeny (Crusio and
Schmitt, 1996) the ﬁrst litter not used for the experiments. Test-
ing involved approximately equal amounts of males and females.
Experiments were carried out during the dark phase of the light–
dark cycle. Behavioral tests and animal care were conducted
according the EU and local ethical guidelines (EU directive 86/609
and Appendix A of the Council of Europe Convention ETS123,
EU decree 2001-486 Decree 214/97 and Spanish law 32/2007) and
approved by the local ethical committee (CEEA-PRBB). All behav-
ioral experiments were carried out with the experimenter blind
to the genotype. Developmental landmarks analyzed include: (i)
assessment of body growth and body length were recorded from
P1, the day of birth; (ii) fur appearance: beginning on P2 appear-
ance of immature fur was observed and fur was deﬁned as the
mature hair being raised; (iii) incisor eruption: beginning on P7
pups were inspected daily for the emergence of both lower and
upper incisor from the gingival; and (iv) eye opening, beginning
on P9 pups were inspected daily for the complete opening of both
eyelids. Neuromotor development was assessed on P7 and P10 by
means of the pivoting and walking tests and general psychomotor
development on P14 by means of the homing test.
In the pivoting locomotion test, the total number of degrees
turned by the pup during a 60-s period was recorded. The test was
performed on a ﬂat surface covered with a paper on which lines
Frontiers in Molecular Neuroscience www.frontiersin.org May 2012 | Volume 5 | Article 58 | 6
Dierssen et al. DREAM regulates neuromotor development
had been drawn to delineate four 90˚ quadrants. The number of
degrees was scored only in completed 90˚ segments.
In the walking test, the latency for a mouse to lift up on all four
legs and walk a distance exceeding its body length was measured
on a ﬂat surface covered with a green paper.
For the homing test, individual pups on postnatal day 14 were
transferred to a cage containing new sawdust in 3/4 and 1/4 of
sawdust of the home litter (“goal arena”). The pups were placed in
the opposite side of the goal arena, near to the wall. The time taken
to reach the home litter sawdust was recorded. A cut-off time of
180 s was applied.
Signiﬁcance of the effects was assessed by two-tailed, unpaired
Student’s t -test was used for comparisons between groups. Analy-
sis was processed using the SPSS program.
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APPENDIX
Table A1 | Functional annotation of over-represented candidate genes according to Gene Ontology (Cellular components).
GO ID Term Probe ID P -value FDR
GO:0005925 Focal adhesion 1417654_at 0.0134524 0.045738
GO:0005615 Etracellular space 1449340_at, 1460049_s_at 0.0050619 0.0286841
GO:0015630 Microtubule cytoskeleton 1438239_at 0.0116782 0.0496325
GO:0043034 Costamere 1417654_at 0.0024424 0.0207604
GO:0042612 MHC class I protein complex 1425545_x_at 0.00211703 0.0359896
Table A2 | Functional annotation of over-represented candidate genes according to Gene Ontology (Biological process).
GO ID Term Probe ID P -value FDR
GO:0007389 Pattern speciﬁcation process 1449340_at 0.0142579 0.0161589
GO:0016055 Wnt receptor signaling pathway 1449340_at 0.0262754 0.0262754
GO:0042475 Odontogenesis of dentin-containing tooth 1449340_at 0.00731229 0.0088792
GO:0006955 Immune response 1425545_x_at 0.0243609 0.0258834
GO:0032874 Positive regulation of stress-activated MAPK cascade 1438239_at 0.00211703 0.00514137
GO:0030514 Negative regulation of BMP signaling pathway 1449340_at 0.00471748 0.0066831
GO:0051894 Positive regulation of focal adhesion assembly 1417654_at 0.000977557 0.00415462
GO:0090398 Cellular senescence 1460049_s_at 0.00130323 0.00443099
GO:0051496 Positive regulation of stress ﬁber assembly 1417654_at 0.00227973 0.00484442
GO:0070314 G1 to G0 transition 1460049_s_at 0.000488878 0.00415546
GO:0045860 Positive regulation of protein kinase activity 1417654_at 0.00504214 0.00659357
GO:0007026 Negative regulation of microtubule depolymerization 1438239_at 0.00260505 0.00492065
GO:0019882 Antigen processing and presentation 1425545_x_at 0.00471748 0.0066831
GO:0008054 Cyclin catabolic process 1460049_s_at 0.000651793 0.00369349
GO:0002474 Antigen processing and presentation of peptide antigen via MHC class I 1425545_x_at 0.00195432 0.00553723
GO:0001916 Positive regulation of T-cell mediated cytotoxicity 1425545_x_at 0.00276768 0.00470505
GO:0002485 Antigen processing and presentation of endogenous peptide antigen via
MHC class I via ER pathway, TAP-dependent
1425545_x_at 0.000488878 0.00415546
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